Requires prescription drug coverage for serious mental illness without prior authorization or utilization management, including step therapy.
Summary
Assembly Bill 4694 would require most New Jersey health insurance carriers, as well as the State Medicaid and NJ FamilyCare programs, to cover prescription drugs used to treat certain serious mental illnesses without prior authorization or other utilization management tools, including step therapy. The bill applies to adults age 18 and older and limits the no-prior-authorization rule to prescriptions written by a psychiatrist or, in the postpartum period, an obstetrician/gynecologist. It also allows another prescriber to continue the same medication without utilization management if the patient has already been stable and appropriately treated on that drug for at least six months.
Beyond the drug-coverage mandate, the bill expands mental health parity oversight. It requires carriers to submit annual reports to the Department of Banking and Insurance describing their medical-necessity criteria and non-quantitative treatment limitations for mental health, substance use disorder, and medical/surgical benefits, along with comparative analyses showing parity compliance. The department would be directed to enforce federal and state parity laws, maintain a redacted consumer complaint log, and issue annual public reports on compliance methods, market conduct examinations, and corrective actions. The bill would take effect 180 days after enactment and apply to policies issued or renewed on or after that date.
Impact
The bill would amend existing New Jersey mental health parity law and add a new Medicaid/NJ FamilyCare coverage requirement, limiting insurers’ and managed care organizations’ ability to impose prior authorization, step therapy, and similar utilization management on specified serious mental illness medications. It would affect private health benefits plans, State Health Benefits Program and School Employees’ Health Benefits Program administrators, Medicaid managed care organizations, and the Department of Banking and Insurance and Division of Medical Assistance and Health Services. The measure also adds reporting, compliance, and public disclosure obligations intended to strengthen enforcement of parity requirements under state and federal law.
Sentiment
The bill’s structure suggests a generally supportive policy approach toward improving access to mental health treatment and reducing administrative barriers to medication. By targeting prior authorization and step therapy for serious mental illness, it reflects a pro-patient, parity-focused sentiment consistent with mental health access advocacy. No committee transcripts or recorded votes were provided, so there is no direct evidence of opposition or support from legislators in the available materials.
Contention
The main points of potential contention are the limits on insurer utilization management and the administrative burden of expanded reporting and compliance review. Carriers may object to the loss of prior authorization and step therapy controls, especially for high-cost medications, and to the requirement to produce detailed parity analyses and data for the department. Another possible issue is the bill’s narrow prescribing rule, which generally restricts the no-prior-authorization protection to prescriptions from psychiatrists or postpartum OB/GYNs, and its age-18-and-over limitation, which could be viewed as excluding younger patients or non-specialist prescribers. The bill also raises implementation questions for Medicaid and NJ FamilyCare managed care organizations that would need to align pharmacy benefit practices with the new mandate.
Carry Over
Requires prescription drug coverage for serious mental illness without prior authorization or utilization management, including step therapy.
Carry Over
Requires prescription drug coverage for serious mental illness without prior authorization or utilization management, including step therapy.